Key clinical point: EG-1962 is no more effective than oral nimodipine in patients with aneurysmal subarachnoid hemorrhage.
Major finding: The proportion of patients with a favorable outcome on the extended Glasgow Outcome Scale was 46% in the EG-1962 arm and 43% in the comparator group.
Study details: A randomized, double-blind, placebo-controlled, international phase 3 trial that included 282 participants.
Disclosures: Several investigators are employees of Edge Therapeutics, which developed EG-1962.
Mayer SA et al. ISC 2019, Abstract LB15.